Daclatasvir (BMS-790052)|cas 1009119-65-6|DC Chemicals

Cas No.:	1009119-65-6
Chemical Name:	Daclatasvir
Synonyms:	BMS790052;Daclatasvir dihydrochloride;BMS790052 HCl;Daclatasvir (BMS-790052);methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl;N,N'-[[1,1'-Biphenyl]-4,4'-diylbis[1H-imidazole-5,2-diyl-(2S)-2,1-pyrrolidinediyl[(1S)-1-(1-methylethyl)-2-oxo-2,1-ethanediyl]]]biscarbamic acid dimethyl ester hydrochloride;BMS-790052 2HCl;BMS790052 dihydrochloride;BMS-790052 dihydrochloride;CS-0270;Daclatasvir;Daclatasvir dihydrochloride (USAN);Daclatasvir hydrochloride (JAN);methyl N-[(2S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methylbutanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl]carbamate,dihydrochloride;Daclatasvir HCL;Daclatasvir API;DACLATASVIR(2HCl);daclatasvir hydrochloride;Dclatasvir dihydrochloride;Daclatavir Dihydrochloride;Daklinza;EBP 883;BMS 790052;C40H50N8O6;LI2427F9CI;methyl N-[(1S)-1-[(2S)-2-[5-[4-[4-[2-[(2S)-1-[(2S)-2-(methoxycarbonylamino)-3-methyl-butanoyl]pyrrolidin-2-yl]-1H-imidazol-5-yl]phenyl]phenyl]-1H-imidazol-2-yl]pyrrolidine-1-carbonyl]-2-methyl-propyl]carbamate;Daclatasvir (USAN);Daclatasvir BMS 790052;MLS006011140;EBP883;SCHE;Daclatasvir 2HCl;BMS790052.2HCl
SMILES:	O=C([C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C(=O)OC([H])([H])[H])N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C1=NC([H])=C(C2C([H])=C([H])C(=C([H])C=2[H])C2C([H])=C([H])C(=C([H])C=2[H])C2=C([H])N=C([C@]3([H])C([H])([H])C([H])([H])C([H])([H])
Formula:	C₄₀H₅₀N₈O₆
M.Wt:	738.875
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

BMS-790052 is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture.IC50 Value: 9-50 pMTarget: HCV NS5ABMS-790052 has broad genotype coverage and exhibits picomolar in vitro potency against genotypes 1a (EC50 50pm) and 1b (EC50 9pm). BMS-790052 produces a robust decline in HCV RNA (-3.6 logs after 48 hours from a single 100 mg) dosefollowing a single dose in patients chronically infected with HCV genotype 1.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC9751	Velpatasvir(GS5816)	Velpatasvir(GS-5816) is a potent and selective Hepatitis C virus NS5A inhibitor.
DC10104	VX222(Lomibuvir)	VCH-222(Lomibuvir) is a novel, potent and selective inhibitor of HCV polymerase with IC50 of 0.94-1.2 μM, 15.3-fold less effective for mutant M423T, and 108-fold less effective for mutant I482L.
DC8190	Ravidasvir hydrochloride (PPI-668)	Ravidasvir(PPI-668) is a NS5A Inhibitor.
DC4121	PSI6130	PSI-6130(R 1656) is a Hepatitis C Virus Nucleoside Inhibitor. PSI-6130(R 1656) is useful for Antiviral agents.
DC10728	Pibrentasvir(ABT-530)	Pibrentasvir is a novel and pan-genotypic hepatitis C virus (HCV) NS5A inhibitor with EC50s ranging from 1.4 to 5.0 pM against HCV replicons containing NS5A from genotypes 1 to 6.
DC8183	Paritaprevir(Veruprevir ABT-450)	NS3/4A protease inhibitor
DC10818	ABT-493(Glecaprevir)	Glecaprevir is a novel HCV NS3/4A protease inhibitor, with IC50 values ranging from 3.5 to 11.3 nM.
DC8238	Danoprevir	Danoprevir is a peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50 of 0.2-3.5 nM, inhibition effect for HCV genotypes 1A/1B/4/5/6 is ~10-fold higher than 2B/3A.
DC7394	Daclatasvir dihydrochloride (BMS-790052)	Daclatasvir (BMS-790052) is a highly selective inhibitor of HCV NS5A with EC50 of 9-50 pM, for a broad range of HCV replicon genotypes and the JFH-1 genotype 2a infectious virus in cell culture.
DC5077	Boceprevir(EBP 520; SCH 503034 )	Boceprevir(EBP 520; SCH 503034 ) is useful for Anti HCV.

Daclatasvir dihydrochloride (BMS-790052)